Audit: QRS - Guggul for Health & Longevity
Audit conducted on 16/08/2026 18:32 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 84 |
| Failed | 0 |
| N/A | 9 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Every QRS statement traces to the ER: protocol cells to ER Therapeutic Protocol (l.360-364), time cells to Practical Considerations (l.421), benefits/risks to the tiered ER headings, monitoring rows to the ER biomarker table (l.453-462). |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “⚠️ Conflicted” on the ER lipid benefit (l.158) and the LDL-C risk (l.238) is carried through as “, conflicted” in benefits_medium and risks_medium. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications stay absolute; cautions stay cautions. No hedge is added or removed. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Benefit- and Risk-Modifying Factors are not surfaced anywhere on the sheet; the CYP3A4 item sits under Contraindications because the ER itself labels it “Absolute contraindication” (l.306). |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT identifiers, author names, or brand names appear anywhere in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | Non-specific attributions (“the multicentre trials”, “the meta-analysis”, “One trial”) all mirror ER phrasing. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Matches the ER’s measured, contested-evidence register. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Expert and data-driven throughout, with the contested lipid case stated neutrally. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | No prescriptive voice; the sheet states what was observed and measured. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Cadence and contraindications are stated descriptively, not as instructions. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No “recommended”, “advised”, or “should” constructions in the document voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronoun appears in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms retained only where the ER decision gate requires them (Child-Pugh, transaminases, CYP3A4); no jargon is added. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every item is a single condensed phrase; explanations, magnitudes, and mechanisms are stripped. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed: no “you” / “your” anywhere in the file. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing assumes a reader tracking ApoB, hs-CRP and thyroid panels against functional rather than conventional ranges. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Three-times-daily dosing with meals, a 10-marker panel and an 8-week re-check are presented without softening for convenience. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | No simplification for a general audience; functional targets are carried through from the ER. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The sheet foregrounds the contested benefit against reliable costs, which is the signal that matters for this audience. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | No occurrence of “anti-aging” or “antiaging”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Formal register throughout (“gastrointestinal intolerance”, “hypersensitivity skin rash”, “adverse” framing); no consumer-grade substitutes. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed headings verified against [qrs_template] and unchanged: Protocol, Time to effect, Benefits, Risk & Side Effects, Monitoring, Qualitative Assessment, Contraindications, Key Interactions, High/Medium/Low/Speculative, Marker/Target/Why. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 38 template span names are present; marker_#* is instantiated 10× and qualitative_item# 7×. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The three website=”…” spans and the page_title wrapper are byte-identical to the template; the CSS block and footer disclaimer are unchanged. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | N/A — no source ER section that maps to a QRS variable is empty. The ER Expected Benefits High tier carries prose, and item 12.5 governs that case (span set to display:none). |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | ER bold labels reused verbatim: “Standard extract dose”, “Standardisation target”, “Crude gum alternative”; marker names match the ER table rows exactly. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No label paraphrased or abbreviated. The time_#_label cells are the only labels without an ER bold-label counterpart, and item 11.4 requires them to be derived from ER content, which they are. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji characters anywhere in the file; tiers are conveyed by labels and CSS only. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Each section is condensed to its shortest faithful form: magnitudes, mechanisms, citations and parenthetical rationale from the ER are all dropped, and no content spills into a second sheet container. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2-14, immediately after <!doctype html> and before the template comment at line 16. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening “—” at line 3, closing “—” at line 13; the lead-in text sits before the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | The block is an HTML comment and is not echoed by any visible element. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values trimmed; only duration is quoted, correctly, because “00:03” contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: guggul_2026-0825-1539_Opus_ER.md — matches the source ER. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.7.02 — matches the version badge at the top of QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-0816-1809 — correct YYYY-MMDD-HHMM form. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | Single word, no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | Nickname plus version number, no additional qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename: guggul_2026-0825-1539_Opus_QRS.html — matches the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified: no stray whitespace and no unnecessary quoting on any key. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | header_topic: “Guggul for Health & Longevity”, matching canonical_topic in the ER frontmatter. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 08/16/2026, correctly derived from qrs_creation_date 2026-0816-1809. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | header_subline_model: Opus 5. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The subline carries only the template-fixed date, source-review link and AI4L attribution; no AKA line, badge or audit stamp was added. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses the ER Conclusion (l.498-500): mechanism, the contested lipid case, and the reliable costs. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 59 words, within the 60-word limit. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause maps to a distinct Conclusion passage — liver switch and inflammatory pathway (l.498), contested lipid case and Western reversal (l.498), rash / digestive complaints / lowered heart-medicine levels (l.500). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | Plain-language throughout: “blood-fat”, “harmful cholesterol”, “heart medicines”, “liver switch”. No acronyms and no clinical-register words. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | Refers only to “South Asian research” and “the most rigorous Western research”; no names, years or sample sizes. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No percentages, mg/dL figures, risk ratios or p-values. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All ten items trace to the ER Key Interactions & Contraindications section (l.300-336). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All nine ER “Populations who should avoid Guggul” bullets plus the one interaction the ER marks “Absolute contraindication” (CYP3A4 narrow-margin substrates, l.306) are present — ten items, complete. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Ten discrete <li> elements inside the [stop_items] span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Mechanistic rationale stripped throughout — e.g. the ER’s emmenagogue explanation (l.328) and the calcineurin-inhibitor gloss (l.330) are dropped. No dash-trailing clauses remain. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Preserved: “(any trimester)”, “(Child-Pugh Class B or C)”, “above three times the upper limit of normal”, “Within 14 days”, “(tacrolimus, ciclosporin)”, “(tacrolimus, ciclosporin, everolimus, apixaban, rivaroxaban)”. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | N/A — the ER Key Interactions & Contraindications section uses no ranking notation inside parentheses; all parentheses hold plain drug or class lists. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | Correctly non-empty: the ER names nine populations that should avoid guggul plus one absolute contraindication. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | N/A — the section is not empty; 10 <li> items are present. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eleven items trace to the ER Key Interactions & Contraindications bullets (l.302-324). |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Eleven of the ER’s twelve interaction bullets are carried; the twelfth (CYP3A4 narrow-margin substrates) is correctly excluded because it appears under Contraindications. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Eleven discrete <li> elements inside the [caution_items] span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every ER mitigation clause is stripped — the four-week lipid panel, the weekly BP check, the eight-week TSH, the four-hour separation. Only the interacting class and its example drugs remain. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | All ER example-drug parentheses preserved verbatim across all eleven items. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | N/A — the ER Key Interactions & Contraindications section uses no ranking notation inside parentheses. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | Correctly non-empty: the ER names twelve interacting classes. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | N/A — the section is not empty; 11 <li> items are present. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Derived from the ER Therapeutic Protocol section (l.358-384). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | The three chosen aspects are the ER’s first three and only dosing-actionable bullets: standard extract dose, standardisation target, crude gum alternative. The remaining bullets are comparative or negative findings. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | N/A — the ER Therapeutic Protocol section supplies three or more distinct actionable aspects; all three action sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine cells populated and ER-traceable — e.g. action_2_sub reflects l.362 (“roughly 30–37 mg guggulsterones daily”; “25 mg three times daily”). |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | All three time facts in the ER (l.421) are surfaced: first lipid change, full lipid effect, skin and joint assessment. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered by benefit magnitude — the two lipid entries (Medium tier benefit) precede skin and joint outcomes (Low tier). |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | N/A — the ER supplies three distinct time-to-effect aspects; all three time sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine cells populated from l.421; time_1_sub and time_3_sub are near-verbatim ER text. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | N/A — the ER Practical Considerations section provides time-to-effect data, so the row is retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Derived from the ER Expected Benefits section (l.150-198). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four variables present in the template order. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Reduced to bare benefit names; the 2021 meta-analysis, the 24-week trial, the 68% acne figure and all mechanistic text are dropped. “, conflicted” is retained because it is the ER’s own evidence flag, not an effect qualifier, and dropping it would strengthen the claim against item 1.3. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content survives; the ER’s “(severe acne with deep lumps and cysts)” gloss and pooled figures are stripped. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER states no benefit reaches the High tier (l.154); [benefits_high] carries style=”display: none” rather than empty-state prose. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Derived from the ER Potential Risks & Side Effects section (l.220-278). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four variables present in the template order. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Reduced to bare risk names; the 9% rash incidence, the 39% GI figure, the 144,600 IU/L creatine kinase value and all mechanistic text are dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content survives; the ER’s rhabdomyolysis and contact-dermatitis glosses are stripped. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | N/A — all four risk tiers (high, medium, low, speculative) carry items in the ER, so no span needs hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the ER Monitoring Protocol & Defining Success section (l.445-462). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All ten ER biomarker rows are present in ER order: LDL-C, ApoB, Total cholesterol, Triglycerides, HDL-C, hs-CRP, TSH, Free T4, ALT and AST, Vitamin D 25-hydroxy. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Populated from l.447-449: baseline, 8-week lipid/liver and conditional thyroid re-check, then every 3 to 6 months. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the qualitative marker list in the ER Monitoring Protocol & Defining Success section (l.464-472). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All seven ER qualitative markers are present in ER order: skin, digestive comfort, energy and heat tolerance, joint pain and stiffness, skin oiliness and lesion count, bruising, muscle symptoms. |
Issues 16/08/2026 18:32
Pass rate 100.00%. No issues found.
Issues 16/08/2026 18:23
- 4.2 / 4.3 — CYP3A4 label paraphrased: The Contraindications item at line 576 reads “Narrow-margin CYP3A4 substrates (tacrolimus, ciclosporin, everolimus, apixaban, rivaroxaban)”, reordering the ER’s bold label “CYP3A4 substrates with narrow margins” (ER line 306), whereas every other gate item carries its ER label verbatim.
Fixes 16/08/2026 18:23
- 4.2 / 4.3 — CYP3A4 label restored verbatim: Changed the Contraindications item at line 576 from “Narrow-margin CYP3A4 substrates (…)” to the ER’s bold label verbatim, “CYP3A4 substrates with narrow margins (tacrolimus, ciclosporin, everolimus, apixaban, rivaroxaban)”.
Issues 16/08/2026 18:13
- 1.4 — Monitoring fact placed in Time to Effect: [time_2_sub] at line 518 appends “the lipid panel is re-checked at 8 weeks”, which is an ER
Risk Mitigation Strategiesitem (ER line 347) rather than a time-to-effect fact, and it duplicates [monitoring_cadence]. - 1.2 — Hedge dropped from vitamin D rationale: [marker_10_why] at line 728 states “No guggul-specific target” where the ER says “No established guggul-specific target” (ER line 462), removing the ER’s hedge.
Fixes 16/08/2026 18:13
- 1.4 — Monitoring fact removed from Time to Effect: [time_2_sub] changed from “Full effect by eight to twelve weeks; the lipid panel is re-checked at 8 weeks” to “The full effect on blood lipids was reached by eight to twelve weeks after starting”, dropping the imported
Risk Mitigation Strategiesmonitoring clause. - 1.2 — Hedge restored on vitamin D rationale: [marker_10_why] changed from “No guggul-specific target; a general fat-soluble status check against own baseline” to “No established guggul-specific target; a general fat-soluble status check against the individual’s own baseline”, matching the ER wording.